Similar Search Results

NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors: Was the Right Question Posed? Were the Best Tools Used?

Getsios, Denis; Migliaccio-Walle, Kristen; Caro, Jaime J. - In: PharmacoEconomics 25 (2007) 12, pp. 997-1006

modelling technologies, basing analyses on a limited subset of the available data, and insufficiently reflecting the uncertainty …

Persistent link: https://www.econbiz.de/10005243114

Long-Term Effects of Second-Generation Cholinesterase Inhibitors on Clinical Outcomes and Costs of Alzheimer

Caro, J. Jaime; Getsios, Denis - In: Disease Management and Health Outcomes 11 (2003) 10, pp. 617-631

Alzheimer Data on the effectiveness of these drugs from information beyond the short-term clinical trials (e.g. long-term clinical trials and non-trial data) are now emerging. In most cases, the results indicate that, at least for some patients, continued treatment with cholinesterase inhibitors...

Persistent link: https://www.econbiz.de/10005404597

Modelling Disease Progression in Alzheimer's Disease: A Review of Modelling Methods used for Cost-Effectiveness Analysis

Green, Colin - In: PharmacoEconomics 25 (2007) 9, pp. 735-750

considered in more detail. The review employs recent guidance on good practice in decision-analytic modelling in HTA to … critically review the modelling methods used. Using this guidance, the models are assessed against the broad criteria of model … the basis for the modelling of treatment effects. It is also clear that studies modelling AD progression, and subsequently …

Persistent link: https://www.econbiz.de/10005404907

Modelling Downstream Effects in the Presence of Technological Change

Mortimer, Duncan - In: PharmacoEconomics 26 (2008) 12, pp. 991-1003

Downstream effects are typically evaluated given current technology and current practice patterns rather than for technology and practice patterns that will be available at the time when downstream effects accrue. Where a relatively short time horizon can be expected to capture all relevant...

Persistent link: https://www.econbiz.de/10005449087

Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer's Disease

Bosanquet, Nick; Yeates, Andrew - In: PharmacoEconomics 24 (2006) 6, pp. 623-625

Persistent link: https://www.econbiz.de/10005590552

Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimer

Jonsson, Linus - In: PharmacoEconomics 21 (2003) 14, pp. 1025-1037

Cholinesterase inhibitors constitute one of few treatment options available for Alzheimer Simulation models can be used to bring together existing data and make predictions of the long-term cost effectiveness of treatment. Most models have been built around cognitive function as a key parameter...

Persistent link: https://www.econbiz.de/10005449007

The Economic Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: Can Drugs Ease the Burden?

Murman, Daniel L.; Colenda, Christopher C. - In: PharmacoEconomics 23 (2005) 3, pp. 227-242

The majority of patients with Alzheimer's disease (AD) will have clinically significant neuropsychiatric symptoms during the course of their disease. There is growing evidence that neuropsychiatric symptoms increase direct costs of care in patients with AD, especially the costs associated with...

Persistent link: https://www.econbiz.de/10005449320

The Authors' Reply

Green, Colin; Picot, Joanna; Loveman, Emma; Takeda, Andrea - In: PharmacoEconomics 24 (2006) 6, pp. 625-626

Persistent link: https://www.econbiz.de/10005404769

Health Utilities in Alzheimer's Disease and Implications for Cost-Effectiveness Analysis

Neumann, Peter J. - In: PharmacoEconomics 23 (2005) 6, pp. 537-541

The National Institute for Health and Clinical Excellence (NICE) provisional decision against memantine and other medications for Alzheimer's disease (AD) has generated much discussion. In its decision, NICE expressed concern about the data source used for the utility scores in the industry...

Persistent link: https://www.econbiz.de/10005590458

Memantine: A Pharmacoeconomic Review of its Use in Moderate-to-Severe Alzheimer's Disease

Plosker, Greg L.; Lyseng-Williamson, Katherine A. - In: PharmacoEconomics 23 (2005) 2, pp. 193-206

Memantine (Ebixa(R), Namenda(TM), Axura(R)) is an uncompetitive NMDA receptor antagonist used in the management of patients with moderate-to-severe Alzheimer's disease. It is currently the only drug approved for use in these more advanced stages of the disease. Significant reductions in...

Persistent link: https://www.econbiz.de/10005243220

1
2
3
4
5
6
7
8
9
10
Next
Last